Article

Some UTIs may be caused by foodborne illness

Some drug-resistant Escherichia coli strains causing urinary tract infections may have an animal origin, according to an article in Clinical Infectious Diseases (2005; 40:251-7).

Related Videos
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Ruchika Talwar, MD, on how urologists can get involved in advocacy
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
Chad Ellimoottil, MD, on how urologists should approach telehealth in changing policy environment
1 expert in this video
BPH: The Patient Journey
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
How recombinant BCG could ease strain of supply issues
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Katherine Chan, MD, on viral vs non-viral vectors in bladder cancer
Dr Louise Kostos answers a question during a Zoom video interview
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
Human kidney stones | Image Credit: © freshidea - stock.adobe.com
Pain management disparities in kidney stones point to need for guidelines, experts say
John Taylor, III, MD, on novel options in NMIBC
John Taylor, III, MD, on novel options in NMIBC
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
FDA testosterone labeling changes: How will they affect prescribing?
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Why a personalized approach is key to prolapse and OAB management
Related Content
Breakthrough Study in Image-Guided Prostate Cancer Treatment
March 31st 2025

Breakthrough Study in Image-Guided Prostate Cancer Treatment

Yale School of Medicine
Published OPTIMUM Trial results compares high-resolution micro-ultrasound with MRI when considering prostate biopsy.
Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management
March 3rd 2025

Episode 4 Video: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates
March 31st 2025

18F-flotufolastat PET/CT shows high inter- and intrareader agreement rates

Phillip Kuo, MD, PhD
"I think a take-home message there is that in the prostate/prostate bed, you have to take extra time and caution in reading that region," says Phillip H. Kuo, MD, PhD.
Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 21st 2025

Episode 4 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
FDA approves durvalumab/chemo for muscle–invasive bladder cancer
March 28th 2025

FDA approves durvalumab/chemo for muscle–invasive bladder cancer

Hannah Clarke
The approval is supported by results from the phase 3 NIAGARA trial.
FDA approves expanded label for 177Lu-PSMA-617 in mCRPC
March 28th 2025

FDA approves expanded label for 177Lu-PSMA-617 in mCRPC

Hannah Clarke
The approval is supported by positive data from the phase 3 PSMAfore trial.
© 2025 MJH Life Sciences

All rights reserved.